Form 4: Collegium Pharmaceutical Director Garen G. Bohlin Reports Stock Grant and Disposal

Director Garen G. Bohlin reports the acquisition of 9,791 shares of Collegium Pharmaceutical common stock through restricted stock units and the disposal of 62,259 shares.

Summary

• On May 15, 2025, Garen G. Bohlin, a director of Collegium Pharmaceutical, acquired 9,791 shares of common stock through a grant of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Collegium Pharmaceutical's common stock.
• The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, contingent upon the director's continued service.
• The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
• Bohlin also disposed of 62,259 shares.
• Following these transactions, Bohlin beneficially owns 62,259 shares of Collegium Pharmaceutical.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. The sentiment is neutral as it simply reports facts without expressing any opinion or forward-looking statements that would indicate a positive or negative outlook.

Positives

• The grant of RSUs to a director aligns their interests with the long-term performance of the company.

Negatives

• The disposal of 62,259 shares by the director could be interpreted negatively by the market.

Risks

• The vesting of RSUs is contingent upon the director's continued service, creating a potential risk if the director leaves the company before the vesting date.
• The disposal of a large number of shares by a director could signal a lack of confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs is tied to the director's continued service and the company's 2026 Annual Meeting of Shareholders, suggesting a focus on long-term stability and performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's sentiment and potential future actions.

Stakeholder Impact

• Shareholders may be interested in the director's stock transactions as an indicator of confidence in the company.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Beneficial Ownership, Director, Garen G. Bohlin, Collegium Pharmaceutical, COLL, Restricted Stock Units, RSUs, Stock Grant, Share Disposal